CRO Sy­neos Health did­n't hold up its end of the deal in en­roll­ment for FSD Phar­ma's tri­al, ar­bi­tra­tion pan­el finds

The con­tract re­search or­ga­ni­za­tion Sy­neos Health didn’t hold up its end of the deal and use “com­mer­cial­ly rea­son­able ef­forts” when set­ting up a tri­al for a biotech client, an ar­bi­tra­tion pan­el found. It al­so de­ter­mined that the client owes the CRO about $1.7 mil­lion in dam­ages — less than half of what Sy­neos was ask­ing for in pay­ment.

FSD Phar­ma, which con­tract­ed Sy­neos to set up a Phase II tri­al in 2021 for one of its drug can­di­dates dubbed FSD 210, claimed in a state­ment Mon­day that Sy­neos failed to en­roll the ex­pect­ed num­ber of pa­tients and hit en­roll­ment dead­lines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA